10.11.2025 / Deals & Cases

Deal: Wenger Vieli advised arcoris bio on its CHF 6.3m seed financing round

Wenger Vieli advised arcoris bio, a Swiss life science research tools and in vitro diagnostics company, on all Swiss legal matters in connection with its CHF 6.3 million seed financing round. The round was co-led by Ventura Ace and ZEISS Ventures, with participation from Zürcher Kantonalbank (ZKB) as well as new and existing private investors.

The financing will enable arcoris bio to advance the development and commercialization of its MUSE® biomarker detection platform. The company will use the funds to accelerate industrialization, expand strategic partnerships, and launch new products.

arcoris bio develops innovative technologies that make it easier and more precise to detect biomarkers in tissue samples. Its MUSE® platform uses nanotechnology to amplify molecular signals, allowing researchers to identify several biomarkers at once with high sensitivity. This makes it possible to analyze biological samples faster and more accurately – an important step for the progress of digital pathology.

The team was led by Beat Speck (Partner, Corporate/M&A) and included Sabine Taxer (Senior Associate, Employment), Andrea Christen (Associate, Notarial Services), Dario Schönbächler (Associate, Corporate/M&A), Cyrill Barmettler (Associate, Corporate/M&A), Samuel Pils (Junior Lawyer) and Michelle Blattmann (Junior Lawyer).